Oncology Biosimilars Market 2018-2026 | Size, Trends, Opportunities and Forecast | Credence Research

Global oncology biosimilars market was valued at US$ 1,651.5 Mn in 2017 expanding at a CAGR of 28.3% from 2018 to 2026.

The latest market report published by Credence Research, Inc. “Oncology Biosimilars Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global oncology biosimilars market was valued at US$ 1,651.5 Mn in 2017 expanding at a CAGR of 28.3% from 2018 to 2026.

Request sample research report @ https://www.credenceresearch.com/sample-request/59205

Market Insights

According to the U.S. Food and Drug Administration (FDA), biosimilar is a biological product that is highly similar to an existing, approved reference product and has no clinically meaningful differences. Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. The number of biosimilar approvals soared in the United States as five of nine approved biosimilars across different disease conditions received U.S. FDA approval. Furthermore, U.S. witnessed the approvals of oncology biosimilars such as Amgen’s Mvasi (bevacizumab-awwb), a biosimilar to Genentech’s Avastin for the treatment of lung, colorectal, kidney, brain and cervical cancers; and Mylan’s Ogivri (trastuzumab-dkst), a biosimilar to Herceptin for treating breast cancer, gastric cancer, and gastrointestinal cancer.

The USFDA is determined to increase biosimilar approvals, especially for cancer as cancer treatment imposes a high cost burden on patients. Although the prices of oncology biosimilars are less compared to biologics, the savings are not on the same scale as compared to generics and patented non-biological drugs. Savings of 20% - 30% compared to the reference biologic product have been observed in major markets such as Europe and North America, making biosimilars as a lucrative alternative.

In terms of drug class, the granulocyte colony-stimulating factor (G-CSF) held the largest share in the oncology biosimilars market owing to its early approvals in Europe and U.S. However, monoclonal antibodies class expected to grow at a highest growth rate and emerge as the largest market in 2026 due to recent approvals of Mvasi (bevacizumab-awwb) and Ogivri (trastuzumab-dkst) in the United States. Moreover, robust pipeline and patent expiration of major biologics during the forecast period would further assist the market growth of monoclonal antibodies.

Browse the full report Oncology Biosimilars Market - Growth, Future Prospects, Competitive Analysis, 2018 – 2026 at https://www.credenceresearch.com/report/oncology-biosimilars-market

In terms of disease condition, neutropenia led the market due to approvals of filgrastim and Peg-filgrastim to multiple pharmaceutical companies in Europe and Asia Pacific. However, breast cancer is projected to proliferate at a humungous rate due to high prevalence of breast cancer globally and recent approval of trastuzumab in Europe and North America.

Europe dominated the global oncology biosimilars market in 2017 due to presence of approved oncology biosimilar such as filgrastim, trastuzumab and rituximab in the region. Moreover, the European Medicines Agency (EMA) have put forth guidelines for the approval of biosimilars through regulatory bodies such as European Society of Medical Oncology (ESMO). North America is anticipated to exhibit rapid growth in oncology biosimilars market due to market entry of breakthrough oncology biosimilars and vigorous pipeline expected to hit the market during the forecast period.

The prominent players actively engaged in the oncology biosimilars market are Samsung Bioepis, Celltrion Inc., Biocon, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Sandoz Inc., Teva Pharmaceutical Industries Ltd., Apotex Inc., and BIOCAD. Robust pipeline and ongoing clinical trials in U.S. and Europe are driving the oncology biosimilars market. For instance, Pfizer has six biosimilars in phase III of clinical trials, testing for drugs such as Rituxan/MabThera, Herceptin, Avastin and Humira

Key Market Movements:

Rising prevalence of cancer worldwide
Recent FDA approved biosimilars contributing towards the growth of oncology biosimilars market
Patent expirations of major biologics leading to inclination of generic pharmaceutical companies to venture in biosimilars
Partnerships and collaboration between biopharmaceutical companies to increase research and development of biosimilars
Robust pipeline of oncology biosimilars anticipated to enter the market by 2020 will also assist market growth

Request sample research report @ https://www.credenceresearch.com/sample-request/59205

The report helps to answer the following questions:
- What is the current size of the Oncology Biosimilars market worldwide?
- How is the Oncology Biosimilars market divided into different product segments?
- How are the overall market and different product segments growing?
- How is the market predicted to develop in the future?


Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Oncology Biosimilars: Market Dynamics and Outlook
Chapter 4. Global Oncology Biosimilars Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Monoclonal Antibodies
4.3. Granulocyte Colony-Stimulating Factor (G-CSF)
4.4. Pipeline Analysis
4.4.1. Phase III Drug Analysis Rituximab Biosimilar Trastuzumab Biosimilar Filgrastim Biosimilar Bevacizumab Biosimilar
4.4.2. Tabular Representation of Phase I and Phase II Drugs

Chapter 5. Global Oncology Biosimilars Market, by Disease Condition, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Breast Cancer
5.3. Lung Cancer
5.4. Colorectal Cancer
5.5. Cervical Cancer
5.6. Blood Cancer
5.7. Neutropenia
5.8. Others (Brain Cancer, Stomach Cancer, etc.)

Request sample research report @ https://www.credenceresearch.com/sample-request/59205

Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Mylan N.V.
7.3. Samsung Bioepis Co. Ltd.
7.4. Teva Pharmaceutical Industries Ltd.
7.5. Pfizer, Inc.
7.6. Celltrion Healthcare
7.7. Novartis International AG
7.8. Biocon Limited
7.9. Biogen Idec
7.10. Sandoz
..................toc continued

About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Related Reports:

Global Chronic Idiopathic Constipation (CIC) Drugs Market By Drug Type (Lubiprostone, Linaclotide, Pipeline Drug Analysis: Phase 3: Plecanatide, Elobixibat, Others), Prescription Type (Prescribed, Over the Counter Drugs) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Opioid Induced Constipation (OIC) Drugs Market By Drug Type (Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Naldemedine, Docusate Sodium, Others), By Prescription Type (Prescribed, Over The Counter) - Growth, Future Prospects And Competitive Analysis, 2018 – 2026

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research Inc
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
Phone: +18003618290
Website: https://www.credenceresearch.com

Release ID: 504469